Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

novel antiplatelet agent that can potentially prevent the formation of deadly blood clots without adding a significant bleeding risk (in Phase III); approximately 13,000 patients have been enrolled in its Phase III program targeted to include 30,000 patients;
  • SIMPONI(TM)* (golimumab), a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. except in Japan and certain other Asian markets;
  • SAPHRIS(TM)** (asenapine), a novel psychopharmacologic agent (under U.S. review for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder); pivotal relapse-prevention data were presented showing that only 12 percent of patients receiving asenapine relapsed at the specified endpoint versus 47 percent of patients receiving placebo;
  • BRIDION(R) (sugammadex), the first and only selective relaxant binding agent for reversing neuromuscular blockade in anesthesia (approved in EU; under review in U.S. and Japan);
  • Boceprevir, an oral protease inhibitor for treating hepatitis C with peginterferon and ribavirin combination therapy (in Phase III); 24-week sustained viral response (SVR) data were presented showing that 75 percent of patients achieved SVR; in addition, a next-generation protease inhibitor in Phase II for treating hepatitis C was unveiled, with the potential to offer once-daily dosing and having 10 times the in vitro potency of current protease inhibitors in late-phase development;
  • Mometasone furoate and formoterol (MFF), an inhaled combination therapy for asthma and COPD (completing Phase III); pivotal data from Phase III trials in asthma were presented showing that MFF met its primary endpoints; and
  • Preladenant, a nov
    '/>"/>

  • SOURCE Schering-Plough Corporation
    Copyright©2008 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
    2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
    3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
    4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
    5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
    6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
    7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
    8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
    11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/14/2014)... , Sept. 14, 2014 /PRNewswire-iReach/ -- "Hematoma Global Clinical ... clinical trial scenario. This report provides elemental information and ... includes an overview of the trial numbers and their ... across the globe. The databook offers a preliminary coverage ... prominence of the sponsors and also provides briefing pertaining ...
    (Date:9/14/2014)... , September 14, 2014 Elbit ... EMITF ) announced today further to the Company,s ... (the "Company,s Previous Reports"), that it was informed by ... US$ 12.5 million by  Shanghai GEOC Hengtong Investment Limited ... the framework of the present investment round in InSightec, ...
    (Date:9/12/2014)... 2014 In the current outcomes-focused market, ... Health Outcomes Liaison (HOL) staff to serve as ... and other important healthcare decision makers. As the ... successful companies will need to understand how to ... To help organizations identify industry trends ...
    Breaking Medicine Technology:Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 2Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 3Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 4Hematoma Therapeutics Clinical Trials Market Overview on Companies, Top Institutes & Clinical Profiles to 2014 5Elbit Imaging Ltd. Announces Investment of US$ 12.5 Million in Insightec by Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited 2Elbit Imaging Ltd. Announces Investment of US$ 12.5 Million in Insightec by Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited 3Pharmaceutical Sector Turning to Health Outcomes Liaisons to Help Industry Navigate Payer-Focused Marketplace 2
    (Date:9/14/2014)... 14, 2014 Adults who are planning ... Quotes Pros website to find quotes for life insurance ... year at http://quotespros.com/life-insurance.html is now delivering the ... partners that are preparing the rates information for adults ... most U.S. states. As a way to simplify the ...
    (Date:9/14/2014)... York, New York (PRWEB) September 14, 2014 ... ) continue to move forward in courts throughout ... a brief filed in San Francisco Superior Court, ... have asked the judge overseeing the proceeding to ... their cases re-transferred to Los Angeles Superior Court. ...
    (Date:9/14/2014)... Top10BestSEOHosting.com always offers truly reliable information ... suppliers carefully, the site has announced that Arvixe ... Best WordPress Hosting suppliers in the current market. ... web hosting provider, and the company’s reputation for ... provider known for its flexible hosting packages, decent ...
    (Date:9/14/2014)... 14, 2014 School requires that children read ... that they be screened only for far vision when they ... away. When their eyes do not track effectively or ... will, at best, avoid reading; at worst, they will ... ability to learn. Children who cannot see cannot read. ...
    (Date:9/13/2014)... PA (PRWEB) September 13, 2014 “I ... air we breathe, especially in major cities, is quite ... Ancaster, Ontario, Canada. “I thought we deserved a healthier ... they invented THE OXYGENIZER. , THE OXYGENIZER prevents pollutants ... and mouth. In doing so, it provides added peace ...
    Breaking Medicine News(10 mins):Health News:Quotes for Life Insurance Now Offered at New Consumer Portal Online 2Health News:DePuy ASR Lawsuit News: Defense Asks Judge Overseeing California Litigation to Deny Opt-Out Plaintiffs’ Re-Transfer Request, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Lawsuit News: Defense Asks Judge Overseeing California Litigation to Deny Opt-Out Plaintiffs’ Re-Transfer Request, Bernstein Liebhard LLP Reports 3Health News:DePuy ASR Lawsuit News: Defense Asks Judge Overseeing California Litigation to Deny Opt-Out Plaintiffs’ Re-Transfer Request, Bernstein Liebhard LLP Reports 4Health News:Top10BestSEOHosting.com: The Best Linux Web Hosting Suppliers Now Unveiled 2Health News:Personal Air Filtering Device Invented by InventHelp Clients (TOR-9166) 2
    ... Nov. 11 Ken Herron, Chief Marketing,Executive at ... announced,today that David S. Novak of the Centers ... team at Online Buddies, Inc. as the site,s ... networking site for,gay men, with 2,000,000 members worldwide, ...
    ... - Global Health,innovator IntraHealth International will participate as ... to improve public health needs in the,West Bank, ... to Washington,DC-based Chemonics International and its subcontractors by ... The new Palestinian Health Sector Reform Project aims ...
    ... In women, habitual snoring may be an independent ... regardless of sleep apnea occurrences. Researchers from Sweden ... aged 20 to 70 years. The apnea-hypopnea index ... loudly and disturbingly often or very often were ...
    ... Germany, Nov. 11 Texas Instruments,(NYSE: ... of more than 15 dedicated,embedded processors which ... clinicians while empowering imaging equipment manufacturers to ... smaller and more portable.,These processors target several ...
    ... his speech today at electronica 2008, Pat O’Doherty, ... spotlighted how sophisticated healthcare semiconductor technology is paving ... and more powerful medical devices for use in ... of devices include those that check glucose levels ...
    ... 85 Americans die by suicide and hundreds of thousands more ... on suicide have focused on identifying psychiatric risk factors. However, ... published online this month in Social Science and Medicine ... closely analyzing the patterns of suicide in a single geographic ...
    Cached Medicine News:Health News:MANHUNT Leads Fight Against Spread of Sexually Transmitted Infections with Launch of MANHUNT Cares; Hires Senior Public Health Strategist from CDC 2Health News:IntraHealth to Support Health Reform in Palestine 2Health News:Journal CHEST: Nov. highlights 2Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 2Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 3Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 4Health News:Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TI's Portfolio of Embedded Processors and Analog Products 5Health News: Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008. 2Health News: Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008. 3Health News:What happens in Vegas? Place as a risk factor for suicide 2
    The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of digoxin in human serum or plasma. Emit 2000 assays are designed for use with most chem...
    Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
    ... (Rapid Plasma Reagin) 18-mm Circle Card ... testing procedures for the serological detection ... of Tests for Syphilis.* The test ... most widely used in the United ...
    ... a non-reactive quality assurance reagent in assays detecting ... IgG and TOXO IgM), IgG and IgM antibodies ... IgG and IgM antibodies to cytomegalovirus (CMV IgG ... herpes simplex virus types 1 and 2 (HSV-1 ...
    Medicine Products: